Anthropic Introduces Claude for Life Sciences to Accelerate Laboratory Research and Drug Discovery

Anthropic has launched Claude for Life Sciences, a specialized AI platform designed to assist researchers, clinical coordinators, and regulatory affairs managers throughout the scientific lifecycle. The initiative marks a shift from using AI as an assistant for isolated tasks, such as writing code or summarizing papers, to integrating it directly into early drug discovery, clinical translation, and commercialization. The launch aligns with Anthropics public benefit mission of accelerating scientific progress.

Outperforming Human Baselines in Laboratory Tasks

At the core of this initiative is the Claude Sonnet 4.5 model, which demonstrates notable performance gains on life science benchmarks. On the Protocol QA evaluation, which measures comprehension of laboratory protocols, Sonnet 4.5 scored 0.83, surpassing both the human baseline of 0.79 and the previous model, Sonnet 4, which scored 0.74. The model also shows significant improvements over its predecessor on BixBench, an evaluation designed to measure performance on bioinformatics tasks.

Seamless Connections and Domain-Specific Skills

To embed the AI into daily research workflows, Anthropic introduced Model Context Protocol connectors that allow Claude to link directly with external platforms. Scientists can query Claude and receive responses containing links back to source experiments, notebooks, and records in Benchling. The system also connects to BioRender for scientific figures and templates, PubMed for biomedical literature, Synapse.org for collaborative data analysis, and Wileys Scholar Gateway for peer-reviewed journal articles. Additionally, the platform introduces a feature called Skills, which are organized folders of instructions and scripts that the AI loads dynamically. The initial skill, single-cell-qc, automates quality control and filtering for single-cell RNA sequencing data following scverse best practices. Claude Code also provides access to custom skills for bioinformatic workflows.

Pharmaceutical Adoption and Enterprise Growth

Major pharmaceutical companies are already deploying the platform to streamline operations. Novo Nordisk utilized Claude to reduce clinical study documentation times from over ten weeks down to just ten minutes. Other industry leaders, including Sanofi, AbbVie, and Genmab, are deploying the system across drug discovery, regulatory compliance, and cancer therapy development. To support these deployments, Anthropic has partnered with consulting firms such as Deloitte, KPMG, PwC, and Slalom. The platform is accessible via Claude.com and the AWS Marketplace, with Google Cloud Marketplace availability planned. This rollout comes amid rapid enterprise growth for Anthropic, which has expanded its business customer base from fewer than 1,000 to more than 300,000, including a massive deployment to 470,000 Deloitte professionals globally.

Cognition and the Future of Scientific Progress

To document this shift, Anthropic launched a dedicated Science Blog to explore how AI is taking on aspects of cognition in research. While AI can identify functional gene relationships across millions of cells, the technology remains in beta, occasionally exhibiting hallucinations, sycophancy, or getting stuck on simple problems. The acceleration of science raises questions about how research apprenticeships will function and how to maintain literature trust when AI is central to its production. As mathematician Timothy Gowers noted, science has entered a brief but enjoyable era where research is greatly accelerated by AI, yet still requires human oversight.

As pharmaceutical giants trade weeks of human documentation for minutes of automated synthesis, the true test for the scientific community will be maintaining rigorous validation standards when the bottleneck of discovery shifts entirely from execution to oversight.